Special issue letter - application note
Received: 12 August 2015
Revised: 18 November 2015
Accepted: 7 January 2016
Published online in Wiley Online Library
(wileyonlinelibrary.com) DOI 10.1002/mrc.4412
Identification of by-products in support of
process development of Muraglitazar
Charles Pathirana,a* Andrew Rusowicz,a Russell Suda,a
Shankar Swaminathana,b and Venkatapuram Palaniswamya,c
Muraglitazar was being developed by Bristol-Myers Squibb for the treatment for type 2 diabetes and dislipidemia. Process
optimization included the minimization of the by-products. This endeavor was greatly facilitated by a clear understanding of
by-product identity. By-products were isolated by preparative chromatography and identified using NMR and MS. The identified
structures of the by-products provided useful information about the undesired side reactions, which were then minimized or
eliminated by altering the reaction conditions appropriately. Copyright © 2016 John Wiley & Sons, Ltd.
Keywords: NMR; 1H NMR; 13C NMR; MS; muaraglitazar; process development; by-products; structural elucidation
are carried over to the API. Identification of a few selected impuri-
ties encountered in the synthesis of muraglitazar is described here.
Introduction
Muraglitazar (1) was being developed by Bristol-Myers Squibb as a
peroxisome proliferator-activated receptor α/γ dual agonist for the
treatment of type 2 diabetes and dislipidemia (Fig. 1).[1–4] 1 was
being synthesized starting from an appropriately substituted oxazole
as shown in Scheme 1.[5,6] During this stage of process development,
characterization of intermediates and the final product is routinely
carried out. In addition, identification of the by-products observed is
also performed routinely for two reasons. First, the identification of
by-products in starting materials, isolated intermediates, and active
pharmaceutical ingredient (API) is required to fulfill regulatory require-
ments. Second, identification of by-products is also carried out to help
optimize the process and to achieve increased overall efficiency and
quality. Identification of any by-product provides increased knowl-
edge of subtle reactant–reagent interactions that may provide in-
sights into how to better control the reaction to achieve the desired
outcome. Therefore, it is crucial to identify the major by-products that
will enable the chemist to make adjustments to minimize their pro-
duction and increase the yield of the desired product. NMR plays a
key role in the identification of by-products and in combination with
mass spectrometry (MS) has been shown to be a comprehensive
approach for complete structural elucidation.[7]
By-product 4 was discovered from the API as the impurity with 1.4
relative retention time (RRT). By-products 9 and 10 were observed
at 1.1 and 0.9 RRT, respectively, in the pre-penultimate 2. By-
product 11 was discovered at 2.2 RRT in the penultimate 3.
Identification of by-product 4
The synthesis of muraglitazar (1) is shown in Scheme 1. An impurity
with a relatively high molecular weight of 980 Da at RRT 1.4 was
observed in the API. The high molecular weight and relatively
non-polar nature of the impurity suggested that this impurity is
resulting from an extended reaction during the final or a previous
synthetic step. The molecular formula of the isolated impurity was
determined to be C54H49N3O15 using electrospray-ionization
high-resolution mass spectrometry (ESI HRMS) [(M + H)+: observed
– 980.3231, calculated – 980.3242]. A ketone carbonyl carbon at δ
189.6 could be assigned using the 1H-13C HMBC correlations arising
from the protons ortho to the aromatic carbon it is attached to at δ
8.08. The entire fragment containing the ketone and the
monosubstituted phenyl ring was easily identified by comparing
the NMR data of 4 and 1 (Table 1). The acetal methine was assigned
using the 1H (δ 7.03, s) and 13C (δ 97.5, CH) chemical shifts. A corre-
lation from this proton to the ketone carbonyl carbon was missing.
However, three-bond correlations through oxygen to the two
The following describes the combined utilization of NMR and MS
to achieve complete identification of several by-products during
process optimization of muraglitazar (1).
Results and discussion
*
Correspondence to: Charles Pathirana, Pharmaceutical Development, Bristol-
Myers Squibb, New Brunswick, NJ 08903, United States. E-mail: charles.
By-products are generally encountered during process develop-
ment for the synthesis of API. International Conference on Harmo-
nization guidelines require knowledge of all the impurities present
in the API at or above 0.1% level. Impurities that fall into this cate-
gory are selected for identification. The level of the impurities is
determined as an area percent from the analysis performed using
reversed phase HPLC. The impurities that are selected for identifi-
cation can be from the API and also from the intermediates if they
a Pharmaceutical Development, Bristol-Myers Squibb, New Brunswick, NJ, 08903,
United States
b Current address: Valeant Pharmaceuticals, 400 Somerset Corporate Blvd,
Bridgewater, NJ, 08807, United States
c
Current address: Novatia, 54 Walker Lane, Newtown, PA, 18940, United States
Magn. Reson. Chem. (2016)
Copyright © 2016 John Wiley & Sons, Ltd.